Neuromeka (348340) Fundamentals 2026 — Revenue Analysis | SniperIQ
Neuromeka (348340) is a KR-listed Industrials company in Industrial - Machinery with a market capitalization of ₩396.5B, trading at ₩30550.00 on the KOE. This SniperIQ fundamentals page covers Neuromeka's valuation, profitability (net margin -214.5%), revenue (₩19.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Neuromeka's market cap?
Neuromeka (348340) has a market capitalization of approximately ₩396.5B, trading at ₩30550.00 on the KOE. Market cap moves with the live share price.
What is Neuromeka's P/E ratio?
Neuromeka's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.2x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is Neuromeka?
Neuromeka runs a net profit margin of -214.5%, a gross margin of 12.7%, and an operating margin of -88.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Neuromeka generate?
Neuromeka reported revenue of ₩19.0B for fiscal year 2025, with net income of -₩22.0B and earnings per share (EPS) of -1932.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Neuromeka pay a dividend?
Neuromeka does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Neuromeka financially healthy?
Neuromeka carries a debt-to-equity ratio of 0.89x and a current ratio of 0.91x, with a market beta of 2.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Neuromeka a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Neuromeka (348340) the key facts are: market cap ₩396.5B, revenue ₩19.0B, 52-week range 19990-139000. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track Neuromeka's full fundamentals live
Get Neuromeka's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.